What is the recommended duration of treatment with Eliquis (apixaban) for its various indications?

Duration of Eliquis (Apixaban) Treatment by Indication

The duration of Eliquis therapy ranges from 10–14 days for post-orthopedic surgery prophylaxis to indefinite treatment for atrial fibrillation and unprovoked venous thromboembolism, with the specific duration determined by the underlying indication and individual thrombotic risk factors. 1, 2

Atrial Fibrillation (Stroke Prevention)

• Indefinite anticoagulation is required for patients with nonvalvular atrial fibrillation at risk for stroke, as the underlying condition persists lifelong. 3, 4
• Treatment should continue without a scheduled stop date unless contraindications develop or the risk-benefit profile changes. 3
• Annual reassessment of bleeding risk and stroke risk is recommended to confirm ongoing appropriateness of therapy. 1

Venous Thromboembolism (VTE) Treatment

Provoked VTE (Surgery, Trauma, or Transient Risk Factor)

• Treat for exactly 3 months with therapeutic-dose apixaban (10 mg twice daily for 7 days, then 5 mg twice daily). 1, 2
• The 2016 CHEST guidelines explicitly recommend against shorter periods, longer time-limited periods (6,12, or 24 months), or extended indefinite therapy for surgically provoked VTE. 2
• Exception: Patients with provoked VTE plus enduring risk factors (e.g., obesity, chronic immobility, active cancer) may benefit from extended reduced-dose therapy (2.5 mg twice daily) after completing 3–6 months of standard treatment. 5, 6

Unprovoked VTE (No Identifiable Trigger)

• Minimum 3–6 months of therapeutic-dose apixaban (10 mg twice daily for 7 days, then 5 mg twice daily). 1, 2
• After completing at least 6 months of full-dose therapy, patients should transition to indefinite anticoagulation using reduced-dose apixaban 2.5 mg twice daily to balance efficacy with bleeding risk. 1, 5
• The 2025 HI-PRO trial demonstrated that apixaban 2.5 mg twice daily for 12 months reduced recurrent VTE from 10.0% (placebo) to 1.3% (apixaban) with only one major bleed in the treatment arm (HR 0.13, P<0.001). 5, 6
• The AMPLIFY-EXT trial confirmed that apixaban 2.5 mg twice daily maintains VTE protection without increasing major bleeding compared to placebo during extended prophylaxis. 1, 4

Cancer-Associated VTE

• Minimum 6 months of therapeutic-dose anticoagulation is recommended, with many patients requiring indefinite treatment while cancer remains active. 1, 7
• After 6 months of full-dose apixaban (5 mg twice daily), patients may transition to reduced-dose 2.5 mg twice daily for extended secondary prevention. 5, 8
• The 2025 API-CAT trial showed that reduced-dose apixaban (2.5 mg twice daily) was non-inferior to full-dose (5 mg twice daily) for preventing recurrent VTE in cancer patients (2.1% vs 2.8%) with significantly lower clinically relevant bleeding (12.1% vs 15.6%; P=0.03). 5
• A 2022 study of 196 cancer patients on low-dose apixaban for 30 months after initial 6-month full-dose treatment reported only 7.6% recurrent VTE and 3.1% major bleeding, with stable low rates beyond 12 months. 8
• Avoid apixaban in gastric or gastroesophageal tumors due to elevated hemorrhage risk; low-molecular-weight heparin is preferred. 5

Post-Orthopedic Surgery Prophylaxis

• Hip replacement: 32–38 days (approximately 5 weeks) of apixaban 2.5 mg twice daily starting 12–24 hours post-surgery. 9, 4
• Knee replacement: 10–14 days (approximately 2 weeks) of apixaban 2.5 mg twice daily starting 12–24 hours post-surgery. 9, 4
• The ADVANCE-3 trial demonstrated that this regimen was superior to enoxaparin for preventing VTE after hip replacement (1.39% vs 3.86%, P<0.0001). 4

Key Dosing Distinctions to Prevent Errors

• VTE treatment maintenance dose is 5 mg twice daily—this must not be confused with the 2.5 mg twice daily dose used for atrial fibrillation in selected patients or for extended VTE prophylaxis. 1, 5
• The atrial fibrillation dose-reduction criteria (age ≥80 years + weight ≤60 kg or serum creatinine ≥1.5 mg/dL) apply only to AF and must never be used for VTE treatment. 5
• Inappropriate under-dosing (using 2.5 mg twice daily for acute VTE) occurs in 4.7%–26.1% of patients and is associated with higher thrombotic events. 5

Renal Impairment Considerations

• Moderate renal impairment (CrCl 30–59 mL/min) does not require dose adjustment for VTE treatment with standard apixaban regimens. 5
• Avoid apixaban when CrCl <15 mL/min; safety and efficacy are uncertain for CrCl <25 mL/min because such patients were excluded from pivotal trials. 5
• Annual renal function reassessment (or sooner if clinically indicated) is necessary because progressive CKD may eventually require alternative anticoagulants. 5

Drug Interaction-Related Duration Adjustments

• When apixaban is co-administered with strong dual P-gp and CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir), reduce the apixaban dose by 50% throughout the treatment course. 5
• Patients already on reduced-dose 2.5 mg twice daily should avoid concomitant use of these strong dual inhibitors, as further dose reduction is not recommended. 5

Common Pitfalls to Avoid

• Do not omit the 7-day loading phase (10 mg twice daily) when initiating apixaban for acute VTE; starting directly at 5 mg twice daily is insufficient. 1, 5
• Do not use reduced-dose apixaban (2.5 mg twice daily) during the initial 6 months of VTE treatment unless specifically indicated for extended secondary prevention after completing standard therapy. 1, 5
• Do not bridge with heparin when starting apixaban for VTE; it can be initiated immediately as monotherapy without parenteral lead-in. 1, 2, 5
• Do not stop anticoagulation at 3 months for unprovoked VTE; these patients require extended or indefinite therapy with dose reduction to 2.5 mg twice daily after 6 months. 1, 2